Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recursion Pharmaceuticals ( (RXRX) ) just unveiled an announcement.
On April 28, 2026, Recursion Pharmaceuticals announced that founder and Chair of the Board Christopher Gibson, Ph.D., informed the company he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders. The company emphasized that his decision was not due to any disagreement over operations, policies, or practices, and he will remain Chair and continue on key board committees until his term ends at the 2026 meeting.
In a follow-up announcement on April 30, 2026, Recursion said Gibson will complete his term through June 2026 and then transition to the role of strategic advisor to the company. CEO Najat Khan and Vice-Chair Rob Hershberg highlighted Gibson’s foundational role and continuing advisory presence as supporting leadership continuity and long-term value creation, signaling a planned, orderly board transition rather than a disruptive governance change.
The most recent analyst rating on (RXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
The score is anchored by mixed fundamentals: a strong cash position and accelerating revenue growth are offset by very large losses and heavy cash burn. Technicals are also weak (below key moving averages with negative MACD), while the latest earnings call was constructive on runway extension, cost reductions, and early clinical proof-of-concept, partially balancing the financial and momentum risks.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company focused on decoding biology to radically improve lives by advancing a portfolio of differentiated investigational medicines. Its wholly owned and partnered pipeline targets oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need across global markets.
The company’s operations are powered by Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates biology, chemistry, and clinical development into a unified intelligence system. With automated biology and chemistry laboratories in Salt Lake City and Milton Park and offices in New York, Montréal, and London, Recursion positions itself at the intersection of AI and scientific innovation.
Recursion leverages proprietary multimodal data, purpose-built AI models, and teams skilled in both science and AI to generate proprietary data at industrial scale. This infrastructure is designed to enable faster and more efficient translation of complex science into impactful medicines, supporting the company’s ambition to deliver meaningful therapeutic advances for patients worldwide.
Average Trading Volume: 15,697,219
Technical Sentiment Signal: Sell
Current Market Cap: $1.74B
See more data about RXRX stock on TipRanks’ Stock Analysis page.